Chesley Taft & Associates LLC Has $929,000 Holdings in Celgene Co. (CELG)

Chesley Taft & Associates LLC cut its position in shares of Celgene Co. (NASDAQ:CELG) by 95.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,905 shares of the biopharmaceutical company’s stock after selling 172,635 shares during the period. Chesley Taft & Associates LLC’s holdings in Celgene were worth $929,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. increased its stake in shares of Celgene by 5.7% during the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after purchasing an additional 3,084,227 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Celgene by 3.1% during the 2nd quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock worth $6,951,579,000 after purchasing an additional 1,610,056 shares during the last quarter. Jennison Associates LLC increased its stake in shares of Celgene by 11.5% during the 3rd quarter. Jennison Associates LLC now owns 14,962,407 shares of the biopharmaceutical company’s stock worth $2,181,818,000 after purchasing an additional 1,546,673 shares during the last quarter. FMR LLC increased its stake in shares of Celgene by 5.9% during the 2nd quarter. FMR LLC now owns 12,594,467 shares of the biopharmaceutical company’s stock worth $1,635,643,000 after purchasing an additional 697,250 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in shares of Celgene by 3.3% during the 2nd quarter. Franklin Resources Inc. now owns 11,080,093 shares of the biopharmaceutical company’s stock worth $1,439,025,000 after purchasing an additional 349,974 shares during the last quarter. Institutional investors own 78.93% of the company’s stock.

In other Celgene news, insider Mark J. Alles bought 3,260 shares of the firm’s stock in a transaction on Thursday, February 8th. The shares were purchased at an average price of $91.90 per share, for a total transaction of $299,594.00. Following the transaction, the insider now directly owns 178,904 shares in the company, valued at approximately $16,441,277.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.95% of the company’s stock.

CELG has been the topic of several recent analyst reports. UBS Group lowered their price objective on shares of Celgene from $153.00 to $146.00 and set a “buy” rating on the stock in a research note on Friday, October 20th. Stifel Nicolaus lowered their price objective on shares of Celgene from $155.00 to $149.00 and set a “buy” rating on the stock in a research note on Friday, October 20th. JPMorgan Chase & Co. restated a “buy” rating on shares of Celgene in a research note on Monday, October 16th. Jefferies Group restated a “buy” rating and set a $160.00 price objective on shares of Celgene in a research note on Monday, October 16th. Finally, Cantor Fitzgerald set a $162.00 price target on shares of Celgene and gave the company a “buy” rating in a research note on Monday, October 16th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $130.35.

Celgene Co. (CELG) opened at $92.51 on Friday. Celgene Co. has a 52-week low of $88.32 and a 52-week high of $147.17. The stock has a market cap of $70,720.00, a P/E ratio of 25.63, a price-to-earnings-growth ratio of 0.65 and a beta of 1.49. The company has a current ratio of 4.99, a quick ratio of 3.52 and a debt-to-equity ratio of 2.29.

Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.78 by $0.09. Celgene had a net margin of 22.38% and a return on equity of 67.50%. The firm had revenue of $3.48 billion for the quarter, compared to analyst estimates of $3.46 billion. During the same quarter in the prior year, the business posted $1.61 EPS. The business’s revenue was up 16.9% compared to the same quarter last year. sell-side analysts expect that Celgene Co. will post 7.68 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2018/02/11/chesley-taft-associates-llc-has-929000-holdings-in-celgene-co-celg.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply